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1-3% of the population suffer from epilepsy. Up to 30% of them develop 
refractory epilepsy and their seizures occur more than once per month 
despite receiving at least 2 first line antiepileptic drugs. In this group, 
more efficacious antiepileptics are needed. This study was undertaken 
to evaluate the efficacy and safety of Oxcarbazepine as an adjunction 
therapy in children with refractory epilepsy.
Materials & Methods
From Feb 2004 until Sep 2006, 30 patients with refractory epilepsy aged 
between 4 and 14 years were evaluated in a before and after type study. 
The patients had seizure ranging from once monthly to more than 10 
times daily and none of them had used Oxcarbazepine previously. They 
received Oxcarbazepine 30 to 50 mg/kg/day orally in combination with 
their current antiepileptic drugs and were regularly assessed for seizure 
frequency and side effects for 10 months. 
Results
With Oxcarbazepine adjunction therapy, 10% of the patients became 
seizure-free, 36.6% experienced more than 50% reduction in seizure 
frequency, and 13.3% had increasing seizures. The drug was especially 
effective in the patients with partial seizures (77.7%). Brief and transient 
adverse effects were seen in 36.6% of the patients which disappeared 
with treatment continuation. Wilcoxon signed ranks test showed that 
oxcarbazepine was effective in the treatment of refractory seizures 
(P=0.003) and as shown by Fisher’s exact test, it was more effective in 
partial seizures (P=0.0043).
Conclusion
The results showed that Oxcarbazepine was a useful medication in the 
treatment of refractory epilepsy, especially the partial type, in children.
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Introduction
Epilepsy is one of the most common neurologic diseases(1). 1-3% of people in the 
world suffer from epilepsy. Mean incidence of epilepsy in childhood (from birth 
to 16 years of age) is approximately 40 in 100,000 children in each year (2).
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Generally used Anti Epileptic Drugs (AED) are 
associated with side effects and drug interactions; 
however, in many epileptic patients, epilepsy is 
controlled after using one of these antiepileptic agents. 
On the other hand, up to 30% of the patients develop 
refractory epilepsy which is frequently common in 
patients with partial seizures (3).
Refractory epilepsy is defined as lack of seizure control 
although the patient has received at least 2 first-line 
AEDs, having more than 1 seizure per month in an 
18-month period (2). When the patient is resistant to 
the medications or cannot tolerate the treatment due 
to the drug’s adverse effects, more efficacious or 
better tolerable medications are needed (4). One of 
these newly introduced medications is Oxcarbazepine 
(OXCBZ) which was approved by Food and Drug 
Administration (FDA) in 2000 for adjunctive therapy of 
epilepsy in children aged over 4 years (5). Many studies 
have shown OXCBZ to be a valuable medication in 
the treatment of partial seizures in children and adults 
both in monotherapeutic or adjunctive settings (6-10). 
OXCBZ is chemically similar to carbamazepine (CBZ) 
but with a different metabolism (11). Its antiepileptic 
effect is due to blockade of voltage-dependant sodium 
channels and modulating calcium channels (7,10), 
it is safer, is tolerated much better, has less drug 
reactions and the risk of over dose is extremely low in 
comparison with CBZ. No significant side effects have 
been reported for OXCBZ  (12). 
This study was performed to evaluate the efficacy and 
safety of OXCBZ in an adjunctive therapeutic setting 
in pediatric patients with resistant epilepsy.
Materials & Methods 
This before and after type study was conducted on 
children with refractory epilepsy, seeking treatment 
in the department of pediatric neurology at Mofid 
children’s hospital. We randomly studied 30 patients 
(based on the average number of patients in similar 
studies). Care was taken to include epileptic patients 
aged 4-14 yr (OXCBZ is approved in epileptic children 
older than 4 yr.) who had refractory epilepsy with 
seizure frequency from once a month to more than 
10 times daily and were not on OXCBZ previously. 
We explained advantages and probable side effects 
of OXCBZ to the patient’s parents and an informed 
consent was obtained from each one. The diagnosis 
of refractory epilepsy was made according to the 
definition of Berg and Shiner (2001) that defined 
intractability as “lack of seizure control while the 
patient has received at least 2 first-line antiepileptic 
medications, having more than 1 seizure per month 
in an 18- month period. Also, the patients should not 
be seizure free for more than 3 consecutive months” 
(2). We collected information such as sex and age 
of patients, seizure type and frequency and AEDs 
history at baseline. Then, we prescribed OXCBZ 
concomitantly with other AEDs that the patients were 
receiving. In the period of treatment with OXCBZ, 
other AEDs were not added but the dosage of current 
AEDs could be changed. The dosage of OXCBZ was 
30 mg/kg/day for the first week and if the seizures 
were not controlled, it was increased to 40 mg/kg/day 
for the second week and finally 50 mg/kg/day for the 
third week if seizures were not controlled again. The 
maintenance dose was then continued for 10 months. 
Their parents kept seizure diaries (in view of frequency, 
duration and type of seizure) and the patients were 
regularly (every two weeks) assessed in the neurology 
clinic for seizure frequency and side effects of the new 
medication. The follow-up period was for 10 months 
(based on similar studies) and we compared daily 
seizure frequency before and after starting the new 
medication. Clinical response to OXCBZ treatment 
was defined as follows: seizure-free status means total 
cessation of seizures, improvement means more than 
50% decrease in seizures frequency, unchanged means 
no notable change observed in seizure frequency and 
worsening means more than 25% increase in seizure 
frequency.
Laboratory investigations (CBC, BUN, Cr, Na, K, Ca, 
P, ALT, AST, U/A) were done in the beginning of the 
study and were re-checked monthly. If any significant 
hematologic, renal, hepatic or systemic side effects 
were seen, the treatment with OXCBZ was stopped 
and the patient was excluded.
Statistical analysis was performed using SPSS version 
11.5 (SPSS; Chicago, IL, USA).  Wilcoxon signed 
rank and Fisher’s exact tests were used to evaluate 
the efficacy of OXCBZ in the treatment of refractory 
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epilepsy in children. Fisher’s exact test was used for 
data analysis of qualitative variables.
Results
Thirty patients with intractable epilepsy were enrolled 
in this before and after type study. Mean age was 7.7±2.9 
yr (range: 4-14 yr) and the group included 20 boys and 
10 girls. The patients had received an average of nine 
AEDs before starting treatment with OXCBZ but their 
seizures were not controlled satisfactorily. During 
the period of treatment with OXCBZ, 18 patients 
(60%) were also receiving 1, 10 patient (33.3%) were 
receiving 2 and 2 patients (6.66%) were receiving 3 
AEDs concomitantly. When seizures were controlled 
after OXCBZ therapy, 9 patients were receiving one 
and 6 were receiving two concomitant AEDs besides 
OXCBZ. 
Nineteen patients (63.3%) had mixed type seizures, nine 
(30%) had partial seizures with or without secondary 
generalization and two (6.6%) had generalized tonic 
colonic seizures.
The effects of OXCBZ add-on therapy on intractable 
epilepsy are shown in table 1. OXCBZ was effective 
in controlling intractable seizure in children (P= 
0.003). The best response was seen in patients with 
partial epilepsy (77.7%) (P=0.0043) and the patients 
with mixed-type seizures showed the least response to 
the drug. The average dose to control seizure was 45 
mg/kg/day. No case of status epilepticus was reported 
during this period.
In one patient, the occurrence of an extensive 
skin rash led to discontinuation of the medication. 
Retrospectively, we found that history of skin reaction 
to CBZ was positive in this patient. In another patient, 
increasing dose of OXCBZ led to diplopia and dizziness 
that disappeared with reduction of the drug dose. 
Other side effects included asymptomatic transient 
hyponatremia (Na=130-132), drowsiness, headache, 
nausea and vomiting, ataxia and agitation (1 patient 
each). All these side effects were seen in the initiation 
of treatment and disappeared after a few days. Overall, 
transient side effects were seen in 11 patients (36.6%) 
but in 1 patient (3.3%), we had to discontinue the 
drug because of the adverse event (skin rash). Serious 
complications including bone marrow suppression and 
hepatic or renal involvement were not detected in any 
of our patients.
Discussion
OXCBZ is a new medication similar to CBZ which 
has a favorable profile. It is rapidly absorbed and 
has a rapid and complete reductive metabolism to 
form active 10-monohydroxy derivative (MHD) 
which is glucorunidated and excreted in the urine, 
with minimal involvement of the hepatic cytochrome 
P450 - dependent enzymes. Oxcarbazepine has no 
autoinduction and has minimal interaction with other 
antiepileptic medications (13). It is quite efficient in 
the treatment of partial seizures in children when is 
administered either alone or in combination with other 
antiepileptic medications (14).
According to our results, in 46.6% of the patients, 
seizures were completely controlled or a minimum 
of 50% reduction in seizure frequency was obtained. 
In a study by Gaily et al., a minimal 50% reduction 
in the frequency of seizures was detected during the 
treatment with OXCBZ in 50% of the patients with 
localization related epilepsy and in 40% of patients 
with generalized epilepsy (15). In the studies by Rufo-
Campas et al and Freidel and colleagues, similar 
results were obtained (16, 17). In a study assessing 
the efficacy of OXCBZ in an adjunctive setting (with 
median dose of 31.4 mg/kg/day), patients with partial 
seizures were evaluated and a 35% reduction in the 
frequency of seizures was detected, whereas this rate 
was 9% in the placebo group (14).
In our study, the best result was seen in patients with 
partial seizures which is in accordance with other 
studies (1, 15, 18, 19). Adverse effects of the drug 
appeared in 40% of our patients. Most common side 
effects of OXCBZ are nausea, vomiting, dizziness, 
fatigue, diplopia, and somnolence (1, 9, 12, 20). These 
side effects are usually transient and disappear with 
dose decrease (9). OXCBZ shows better tolerability 
and safety than CBZ which is due to absence of 10-
11 epoximetabolites of CBZ, less drug interaction 
with other antiepileptics, less risk of overdose for the 
patient, and no severe hematologic, renal, hepatic or 
nervous system side effects (2,12) . In 3% of the patients 
(regardless of age), asymptomatic hyponatremia is 
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detected, most frequently in the patients predisposed to 
hyponatremia (because of diseases or medications such 
as diuretics or non steroidal anti inflammatory drugs) 
(6, 9). Hyponatremia generally improves a few days 
after discontinuation of the medication (21). Therefore, 
measurement of the baseline serum sodium level is 
not necessary except for the conditions mentioned 
above. When the patient is on the maintenance therapy 
with OXCBZ, the serum level of sodium should also 
be measured when the symptoms of hyponatremia 
develop (6). The risk of symptomatic hyponatremia is 
greater when the child has an infection or the seizure 
is prolonged (21). In our study, one patient (3.33%) 
developed asymptomatic hyponatremia in the first 
week of treatment.
Allergic skin reactions are rare and develop mostly 
within the 3 first months of the treatment (21). Cross 
reactivity is also detected in 25% of the patients who 
are hypersensitive to CBZ (22). In our study, one 
patient (3.33%) developed a skin rash in the first week 
of treatment. She had the history of developing a skin 
rash to CBZ previously. The uncommon side effects 
of OXCBZ include abdominal pain, acne, alopecia, 
apathy, diarrhea, gum hyperplasia, tremor, and weight 
gain (21). None of these side effects were seen in our 
patients. Based on other researches done so far, in 
patients with mild to moderate hepatic dysfunction, no 
adjustment in the dose of OXCBZ is needed (7, 23).
In conclusion, OXCBZ is a favorable medication in 
the treatment of epilepsy, especially partial seizures, 
in children. We observed some advantages of the 
drug including rapid titration, low rate of drug-drug 
interaction, low rate of serious side effects and good 
tolerability and safety. Also, based on other research 
done so far, there is no need for monitoring laboratory 
findings of the patients. 
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